XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.23.1

Supplemental Balance Sheet Information | 6 Months Ended
--- | ---
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract] |
Supplemental Balance Sheet Information | 5. Supplemental Balance Sheet Information Inventories Inventories consisted of the following components:
| March 31, |  |  | September 30, |
(In thousands) | 2023 |  |  | 2022 |
Raw materials | $ | 8,262 |  |  | $ | 6,102 |
Work-in process |  | 2,083 |  |  |  | 1,595 |
Finished products |  | 3,422 |  |  |  | 4,122 |
Total | $ | 13,767 |  |  | $ | 11,819 |
Prepaids and Other Assets, Current Prepaids and other current assets consisted of the following:
| March 31, |  |  | September 30, |
(In thousands) | 2023 |  |  | 2022 |
Prepaid expenses | $ | 4,034 |  |  | $ | 2,570 |
Irish research and development credits receivable |  | 836 |  |  |  | 753 |
CARES Act employee retention credit receivable (1) |  | 3,441 |  |  |  | 3,441 |
Prepaids and other | $ | 8,311 |  |  | $ | 6,764 |
(1) Receivable consisted of anticipated reimbursement of personnel expenses incurred in fiscal periods prior to fiscal 2023 as a result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). Intangible Assets Intangible assets consisted of the following:
| March 31, 2023 |
(Dollars in thousands) | Weighted Average Original Life (Years) |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net |
Definite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |
Customer lists and relationships |  | 8.9 |  |  | $ | 12,476 |  |  | $ | (10,160 | ) |  | $ | 2,316 |
Developed technology |  | 11.9 |  |  |  | 34,708 |  |  |  | (9,883 | ) |  |  | 24,825 |
Patents and other |  | 14.1 |  |  |  | 3,551 |  |  |  | (2,546 | ) |  |  | 1,005 |
Total definite-lived intangible assets |  |  |  |  | 50,735 |  |  |  | (22,589 | ) |  |  | 28,146 |
Unamortized intangible assets: |  |  |  |  |  |  |  |  |  |  |
Trademarks and trade names |  |  |  |  | 580 |  |  |  | — |  |  |  | 580 |
Total intangible assets |  |  |  | $ | 51,315 |  |  | $ | (22,589 | ) |  | $ | 28,726 |
| September 30, 2022 |
(Dollars in thousands) | Weighted Average Original Life (Years) |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net |
Definite-lived intangible assets: |  |  |  |  |  |  |  |  |  |  |
Customer lists and relationships |  | 8.9 |  |  | $ | 11,354 |  |  | $ | (8,827 | ) |  | $ | 2,527 |
Developed technology |  | 11.9 |  |  |  | 31,943 |  |  |  | (7,994 | ) |  |  | 23,949 |
Patents and other |  | 14.1 |  |  |  | 3,551 |  |  |  | (2,462 | ) |  |  | 1,089 |
Total definite-lived intangible assets |  |  |  |  | 46,848 |  |  |  | (19,283 | ) |  |  | 27,565 |
Unamortized intangible assets: |  |  |  |  |  |  |  |  |  |  |
Trademarks and trade names |  |  |  |  | 580 |  |  |  | — |  |  |  | 580 |
Total intangible assets |  |  |  | $ | 47,428 |  |  | $ | (19,283 | ) |  | $ | 28,145 |
Intangible asset amortization expense was $0.9 million and $1.1 million for the three months ended March 31, 2023 and 2022, respectively, and $1.9 million and $2.3 million for the six months ended March 31, 2023 and 2022, respectively. Based on the intangible assets in service as of March 31, 2023, estimated amortization expense for future fiscal years was as follows:
(In thousands) |  |
Remainder of 2023 | $ | 1,888 |
2024 |  | 3,777 |
2025 |  | 3,741 |
2026 |  | 2,844 |
2027 |  | 2,593 |
2028 |  | 2,582 |
Thereafter |  | 10,721 |
Definite-lived intangible assets | $ | 28,146 |
Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors. Goodwill Changes in the carrying amount of goodwill by segment were as follows:
(In thousands) | In Vitro Diagnostics |  |  | Medical Device |  |  | Total |
Goodwill as of September 30, 2022 | $ | 8,010 |  |  | $ | 32,700 |  |  | $ | 40,710 |
Currency translation adjustment |  | — |  |  |  | 3,113 |  |  |  | 3,113 |
Goodwill as of March 31, 2023 | $ | 8,010 |  |  | $ | 35,813 |  |  | $ | 43,823 |
Other Assets, Noncurrent Other noncurrent assets consisted of the following:
| March 31, |  |  | September 30, |
(In thousands) | 2023 |  |  | 2022 |
Operating lease right-of-use assets | $ | 3,319 |  |  | $ | 3,633 |
Other |  | 1,437 |  |  |  | 1,136 |
Other assets | $ | 4,756 |  |  | $ | 4,769 |
Other noncurrent assets consisted primarily of prepaid expenses and receivables related to refundable Irish research and development tax credits. Accrued Other Liabilities Accrued other liabilities consisted of the following:
| March 31, |  |  | September 30, |
(In thousands) | 2023 |  |  | 2022 |
Accrued professional fees | $ | 413 |  |  | $ | 279 |
Accrued clinical study expense |  | 1,896 |  |  |  | 1,425 |
Accrued purchases |  | 1,297 |  |  |  | 1,655 |
Acquisition of in-process research and development (1) |  | 967 |  |  |  | 981 |
Income tax payable |  | 36 |  |  |  | — |
Restructuring (2) |  | 308 |  |  |  | — |
Operating lease liability, current portion |  | 1,044 |  |  |  | 963 |
Other |  | 502 |  |  |  | 551 |
Total accrued other liabilities | $ | 6,463 |  |  | $ | 5,854 |
(1) Acquisition of in-process research and development consisted of the present value of guaranteed payments to be made (current portion) in connection with an asset acquisition in fiscal 2018 (Note 11). (2) Restructuring consisted of accrued severance and related expenses associated with a workforce restructuring initiated in the second quarter of fiscal 2023 (Note 12). Other Long-term Liabilities Other long-term liabilities consisted of the following:
| March 31, |  |  | September 30, |
(In thousands) | 2023 |  |  | 2022 |
Deferred consideration (1) | $ | 3,404 |  |  | $ | 4,260 |
Contingent consideration (2) |  | 835 |  |  |  | 829 |
Unrecognized tax benefits (3) |  | 1,997 |  |  |  | 1,841 |
Operating lease liabilities (4) |  | 3,317 |  |  |  | 3,843 |
Other |  | 189 |  |  |  | — |
Other long-term liabilities | $ | 9,742 |  |  | $ | 10,773 |
(1) Deferred consideration consisted of the present value of guaranteed payments to be made (noncurrent portion) in connection with the fiscal 2021 Vetex acquisition and with an asset acquisition in fiscal 2018 (Note 11). (2) Contingent consideration consisted of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 11). (3) Balance of unrecognized tax benefits (Note 10) includes accrued interest and penalties, if applicable. (4) Operating lease liabilities consisted of the non-current portion of the net present value of future minimum lease payments, reduced by the discounted value of leasehold improvement incentives paid or payable to the Company.

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration